More evidence for benefits of Rapamycin

April, 2010

Another study using a different strain of genetically engineered mice has confirmed the finding that the transplant drug rapamycin prevented cognitive impairment.

A few months ago, I reported on an exciting finding that rapamycin, a drug currently used in transplant patients, improved memory in Alzheimer's mice. Now a different strain of mice (ones engineered to have defects in the genes that make amyloid precursor protein) has also shown improvements in learning and memory, correlated with less damage in brain tissue, after rapamycin treatment lowered levels of amyloid-beta-42. The mice given the drug performed at levels comparable with normal mice.

Reference: 

Related News

Although HIV doesn't directly infect neurons, it appears that once it has crossed the blood-brain barrier, it affects supporting cells that can release immune factors that harm neurons.

A study (“Midlife in the United States”) assessing 3,343 men and women aged 32-84 (mean age 56), of whom almost 40% had at least a 4-year college degree, has found evidence that frequent cognitive activity can counteract the detrimental effect of poor education on age-related cognitive decline.

Previous research has shown that older adults are more likely to incorrectly repeat an action in situations where a

It’s now well established that older brains tend to find it harder to filter out irrelevant information. But now a new study suggests that that isn’t all bad.

A study involving 155 women aged 65-75 has found that those who participated in resistance training once or twice weekly for a year significantly improved their selective attention (maintaining mental focus) and conflict resolution (as well as muscular function of course!), compared to those who

A number of rodent studies have shown that blueberries can improve aging memory; now for the first time, a human study provides evidence.

A study involving 57 cognitively healthy older adults has found that those who showed decreased memory performance two years later (20 of the 57) had higher baseline levels of phosphorylated tau231 in the

Midlife hypertension has been confirmed as a risk factor for the development of dementia in late life, but there have been conflicting findings about the role of late-life hypertension.

By following 597 Alzheimer’s patients over 15 years, researchers have determined that a simple progression rate can be calculated at the initial visit, using symptom onset and present performance, and that this can reliably identify slow, intermediate and rapid progression.

Pages

Subscribe to Latest newsSubscribe to Latest newsSubscribe to Latest health newsSubscribe to Latest news